Beijing Bohui Innovation Technology Co Ltd (SHE:300318) — Market Cap & Net Worth
Market Cap & Net Worth: Beijing Bohui Innovation Technology Co Ltd (300318)
Beijing Bohui Innovation Technology Co Ltd (SHE:300318) has a market capitalization of $584.54 Million (CN¥3.99 Billion) as of September 19, 2026. Listed on the SHE stock exchange, this China-based company holds position #11537 globally and #3274 in its home market, demonstrating a -3.17% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Beijing Bohui Innovation Technology Co Ltd's stock price CN¥4.89 by its total outstanding shares 816900495 (816.90 Million). Also see 300318 current and non-current assets for a full breakdown of the balance sheet.
Beijing Bohui Innovation Technology Co Ltd Market Cap History: 2015 to 2026
Beijing Bohui Innovation Technology Co Ltd's market capitalization history from 2015 to 2026. Data shows change from $1.57 Billion to $584.54 Million (-7.49% CAGR). Also see Beijing Bohui Innovation Technology Co L cash flow conversion for how efficiently the company converts equity into cash flow.
Beijing Bohui Innovation Technology Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Beijing Bohui Innovation Technology Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check Beijing Bohui Innovation Technology Co L (300318) share price today for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
0.80x
Beijing Bohui Innovation Technology Co Ltd's market cap is 0.80 times its annual revenue
Latest Price to Earnings (P/E) Ratio
73.95x
Beijing Bohui Innovation Technology Co Ltd's market cap is 73.95 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $1.57 Billion | $268.85 Million | $11.88 Million | 5.85x | 132.32x |
| 2016 | $1.08 Billion | $404.05 Million | $23.60 Million | 2.68x | 45.82x |
| 2017 | $644.78 Million | $443.75 Million | $38.85 Million | 1.45x | 16.60x |
| 2018 | $475.76 Million | $622.09 Million | $69.44 Million | 0.76x | 6.85x |
| 2019 | $488.91 Million | $628.34 Million | $2.54 Million | 0.78x | 192.28x |
| 2020 | $1.43 Billion | $738.72 Million | $7.50 Million | 1.94x | 190.52x |
| 2021 | $1.18 Billion | $714.75 Million | -$322.18 Million | 1.66x | N/A |
| 2022 | $699.30 Million | $795.93 Million | -$78.33 Million | 0.88x | N/A |
| 2023 | $745.92 Million | $1.05 Billion | -$24.93 Million | 0.71x | N/A |
| 2024 | $683.76 Million | $851.69 Million | $9.25 Million | 0.80x | 73.95x |
Competitor Companies of 300318 by Market Capitalization
Companies near Beijing Bohui Innovation Technology Co Ltd in the global market cap rankings as of September 19, 2026. Review how tangible is Beijing Bohui Innovation Technology Co L's equity to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Beijing Bohui Innovation Technology Co Ltd by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #189 globally with a market cap of $128.84 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #340 globally with a market cap of $79.38 Billion USD.
- CSL Ltd (AU:CSL): Ranked #459 globally with a market cap of $60.28 Billion USD ( AU$85.19 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #505 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #189 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $128.84 Billion | $508.34 |
| #340 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $79.38 Billion | $784.85 |
| #459 | CSL Ltd | AU:CSL | $60.28 Billion | AU$175.59 |
| #505 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $154.04 |
Beijing Bohui Innovation Technology Co Ltd Historical Marketcap From 2015 to 2026
Between 2015 and today, Beijing Bohui Innovation Technology Co Ltd's market cap moved from $1.57 Billion to $ 584.54 Million, with a yearly change of -7.49%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥584.54 Million | -22.01% |
| 2025 | CN¥749.50 Million | +9.62% |
| 2024 | CN¥683.76 Million | -8.33% |
| 2023 | CN¥745.92 Million | +6.67% |
| 2022 | CN¥699.30 Million | -40.97% |
| 2021 | CN¥1.18 Billion | -17.14% |
| 2020 | CN¥1.43 Billion | +192.42% |
| 2019 | CN¥488.91 Million | +2.76% |
| 2018 | CN¥475.76 Million | -26.21% |
| 2017 | CN¥644.78 Million | -40.37% |
| 2016 | CN¥1.08 Billion | -31.22% |
| 2015 | CN¥1.57 Billion | -- |
End of Day Market Cap According to Different Sources
On Sep 19th, 2026 the market cap of Beijing Bohui Innovation Technology Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $584.54 Million USD |
| MoneyControl | $584.54 Million USD |
| MarketWatch | $584.54 Million USD |
| marketcap.company | $584.54 Million USD |
| Reuters | $584.54 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Beijing Bohui Innovation Technology Co Ltd
Beijing Bohui Innovation Biotechnology Group Co., Ltd. engages in the research and development, production, sale, and after-sale service of diagnostic products in China. The company offers human immunoglobulin for rabies, tetanus, hepatitis B, and intravenous injections; albumin; human prothrombin complex; and vaccine for rabies. It also provides molecular platform, such as Automatic Real-time Fl… Read more